Organization (Academic)
Universidade Federal de Goiás
ClinicalTrials.gov lists Universidade Federal de Goiás as lead sponsor of 42 trials. It has 2 active development programs and 21 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo UFG, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Universidade Federal de Goiás: 42 lead-sponsored trials and 1 legal-entity registration.
Disease areas (50)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Mouth, Edentulous | 8 |
| Pain | 5 |
| Inflammation | 4 |
| Anxiety Disorders | 3 |
| Dental Caries | 3 |
Showing 5 of 50 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2021 | 4 |
| 2020 | 3 |
| 2018 | 3 |
| 2017 | 10 |
| 2016 | 4 |
| 2015 | 3 |
| 2014 | 2 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Aerobic exercise | Anxiety Disorders | Not reported | 1 |
| Aerobic exercise | Sleep Initiation and Maintenance Disorders | Not reported | 1 |
Approved assets (21)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| MIDAZOLAM | 2 |
| (R,S)-ketamine (Pilot I) | 2 |
| Intranasal Ketamine | 1 |
| Reinforced vaccination schedule | 1 |
| Ketamine 50 MG/ML | 1 |
Showing 5 of 21 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 30% hit target (n=10) | 33% on time (n=12) |
Journals published in (127)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Clinical oral implants research | 8 |
| Journal of oral rehabilitation | 8 |
| Journal of dental research | 4 |
| Journal of dentistry | 4 |
| Nutrients | 4 |
Showing 5 of 127 journals.
Organization relationships (23)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Universidade Federal de Minas Gerais | Co sponsors trial with | 1 |
| European Union | Co sponsors trial with | 1 |
| Universidade Federal de São Paulo | Co sponsors trial with | 1 |
| Universidade de Brasília | Co sponsors trial with | 1 |
| Industrial University of Santander | Co sponsors trial with | 1 |
Showing 5 of 23 relationships.
Latest dated events (49)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-10-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-04-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-07-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 49 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| PSEN1 | Trial sponsor | Named in trial inclusion criteria |
| PSEN1 | Trial sponsor | Named in trial inclusion criteria |
| ERVK-10 | Trial sponsor | Mentioned in trial text |
| ERVK-18 | Trial sponsor | Mentioned in trial text |
| ERVK-19 | Trial sponsor | Mentioned in trial text |
Showing 5 of 16 evidence rows.
Biomarkers this organization publishes on (98)
Shown in this order: most publications first.
Showing 5 of 98 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.